Pfizer Q3 cull sees midstage fast-tracked NASH drug axed, with a cancer vaccine and arthritis asset also chopped

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

In what is now a quarterly tradition, Pfizer announced the cuts in its third-quarter financials today.

The first cull is for phase 2 nonalcoholic steatohepatitis (NASH) drug PF-05221304, which has an FDA fast-track tag. Pfizer was testing it as an acetyl-CoA carboxylase inhibitor in those with liver scarring as a monotherapy.